HC Wainwright Issues Positive Estimate for PolyPid Earnings

PolyPid Ltd. (NASDAQ:PYPD – Free Report) – Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for PolyPid in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst B. Folkes now expects that the company will earn ($1.41) per share for the year, up from their prior forecast of ($1.67). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.21) EPS.

PolyPid (NASDAQ:PYPD – Get Free Report) last issued its quarterly earnings results on Wednesday, November 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.91 by ($1.15). The firm had revenue of $30.00 million during the quarter, compared to the consensus estimate of $30.00 million.

PYPD has been the subject of several other research reports. Oppenheimer initiated coverage on PolyPid in a research note on Tuesday, October 27th. They set an “outperform” rating and a $10.00 target price for the company. Craig Hallum set a $12.00 price target on PolyPid in a research report on Wednesday, July 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a research report on Friday, September 18th. Finally, Wall Street Zen lowered PolyPid from a “buy” rating to a “hold” rating in a report on Saturday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Check Out Our Latest Analysis on PolyPid

PolyPid Stock Performance

PolyPid stock opened at $6.26 on Monday. PolyPid has a 52 week low of $3.50 and a 52 week high of $7.15. The firm has a market capitalization of $119.46 million, a PE ratio of -4.64 and a beta of 1.43. The business’s 50-day simple moving average is $5.37 and its 200-day simple moving average is $4.80.

Institutional Trading of PolyPid

A number of hedge funds have recently bought and sold shares of the stock. HighTower Advisors LLC grew its position in PolyPid by 18.2% in the 3rd quarter. HighTower Advisors LLC now owns 13,000 shares of the company’s stock worth $69,000 after purchasing an additional 2,000 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its position in shares of PolyPid by 32.7% during the third quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock valued at $106,000 after buying an additional 4,955 shares during the last quarter. AXQ Capital LP acquired a new position in shares of PolyPid during the second quarter valued at about $87,000. Renaissance Technologies LLC acquired a new position in shares of PolyPid during the first quarter valued at about $81,000. Finally, Connective Capital Management LLC acquired a new position in shares of PolyPid during the second quarter valued at about $343,000. 26.47% of the stock is owned by institutional investors.

About PolyPid

(Get Free Report)

PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered. The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections.

See Also

Earnings History and Estimates for PolyPid (NASDAQ:PYPD)

Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.